Cargando…

Target Therapies in Lung Cancer

Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bearz, A., Berretta, M., Lleshi, A., Tirelli, U.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085512/ https://www.ncbi.nlm.nih.gov/pubmed/21541198 http://dx.doi.org/10.1155/2011/921231

Ejemplares similares

Comment on ‘Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection’
por: Bearz, A, et al.
Publicado: (2012)

Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
por: de Scordilli, Marco, et al.
Publicado: (2022)

Two types of fatigue in cancer patients
por: Giacalone, A, et al.
Publicado: (2012)

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
por: De Carlo, Elisa, et al.
Publicado: (2022)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
por: Bearz, Alessandra, et al.
Publicado: (2012)

Immune checkpoint inhibitors and response analysis: a tough challenge. A case report
por: Bearz, Alessandra, et al.
Publicado: (2016)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
por: Stanzione, Brigida, et al.
Publicado: (2023)

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
por: Russo, Francesca, et al.
Publicado: (2008)

Hodgkin's Disease in Patients with HIV Infection
por: Spina, Michele, et al.
Publicado: (2011)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
por: Del Conte, Alessandro, et al.
Publicado: (2022)

Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology
por: Crisci, Stefania, et al.
Publicado: (2019)

Personalized Targeted Therapy for Lung Cancer
por: Wu, Kehua, et al.
Publicado: (2012)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
por: Gridelli, Cesare, et al.
Publicado: (2023)

A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
por: Tirelli, Umberto, et al.
Publicado: (2020)

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
por: Michelotti, Anna, et al.
Publicado: (2022)

Advances in target therapy in lung cancer
por: Sculier, Jean-Paul, et al.
Publicado: (2015)

Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors
por: Silva, Ana P. S., et al.
Publicado: (2016)

Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Targeted therapies and immunotherapy in non-small-cell lung cancer
por: Cortinovis, D, et al.
Publicado: (2016)

Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature
por: Berretta, M., et al.
Publicado: (2022)

Targeted therapies for advanced non-small cell lung cancer
por: Ai, Xiaojuan, et al.
Publicado: (2018)

Targeted therapies in non-small cell lung cancer
por: Kyle, Fiona, et al.
Publicado: (2008)

Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
por: Kwon, Jennifer, et al.
Publicado: (2012)

Magnetic particle targeting for diagnosis and therapy of lung cancers
por: Saadat, Mahsa, et al.
Publicado: (2020)

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
por: Rivera-Concepcion, Joel, et al.
Publicado: (2022)

Lung cancer-initiating cells: a novel target for cancer therapy
por: Morrison, Brian J., et al.
Publicado: (2013)

Recent advances of novel targeted therapy in non-small cell lung cancer
por: Katzel, Jed A, et al.
Publicado: (2009)

The steady progress of targeted therapies, promising advances for lung cancer
por: Bombardelli, Lorenzo, et al.
Publicado: (2016)

Osimertinib making a breakthrough in lung cancer targeted therapy
por: Zhang, Haijun
Publicado: (2016)

Targeted drugs for systemic therapy of lung cancer with brain metastases
por: Sun, Ya-Wen, et al.
Publicado: (2017)

Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer
por: Allaeys, Toon, et al.
Publicado: (2021)

New Targeted Therapy for Non-Small Cell Lung Cancer
por: Chung, Eun Ki, et al.
Publicado: (2023)

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer
por: Ortega, Miguel A., et al.
Publicado: (2023)

Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Targeted therapies in development for non-small cell lung cancer
por: Reungwetwattana, Thanyanan, et al.
Publicado: (2013)

Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges
por: Chen, Yuchen, et al.
Publicado: (2018)

Ferroptosis: A New Promising Target for Lung Cancer Therapy
por: Xiong, Rui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l6bfqa3c4ebef8hmau9u56eo30